From sympathetic storm to systemic inflammation: spatiotemporal dynamics of the brain-lung axis in neurogenic pulmonary edema
Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis
Lassa fever countermeasures gather pace
Nature Medicine, Published online: 03 July 2026; doi:10.1038/s41591-026-04478-4
Two early phase clinical trials represent progress in Lassa fever vaccine and therapeutic development, including the first interventional treatment trial in decades.
Generalizable AI predicts immunotherapy outcomes across cancers and treatments
Nature Medicine, Published online: 03 July 2026; doi:10.1038/s41591-026-04502-7
COMPASS is a pan-cancer foundation model that predicts immunotherapy response, across cancer types and treatments, from bulk tumor transcriptomes.
Immune aging biomarkers for clinical trials
Nature Medicine, Published online: 03 July 2026; doi:10.1038/s41591-026-04493-5
The authors present a framework for the selection of immune aging biomarkers suitable for clinical trials in geroscience, alongside a translational roadmap for biomarker development to support the next generation of clinical studies on immune aging.
Why high scores do not mean application readiness for health AI
Nature Medicine, Published online: 02 July 2026; doi:10.1038/s41591-026-04500-9
Large language models achieve high scores on health application benchmarks, yet adversarial stress tests now reveal prevalent brittleness — shortcut reliance, fragile visual grounding and fabricated reasoning traces — which exposes substantial gaps between benchmark performance and the robustness evidence needed to support claims of readiness for medical decision-support and patient-facing applications.
Synthetic Organizers Aid Creation of Reproducible Kidney Organoids from Stem Cells
University of Southern California (USC) researchers have paired a biological discovery with an engineering feat to create more faithful, reproducible kidney organoid structures, grown from human pluripotent stem cells (hPSCs). By mapping the developing human kidney, the scientists identified a previously unrecognized developmental axis that helps organize the kidney’s nephrons, which are their filtering units. The team then engineered Wnt-secreting “synthetic organizer” cells to recreate aspects of this developmental environment in organoids.
Their advance makes the organoids more reliable models for studying disease and evaluating potential therapies, while supporting long-term efforts to generate transplantable kidney tissue. “It is important that we’re starting to get good reproducibility from organoid models that can lead to robust preclinical models of cell function and disease to benefit patients,” said Nils Lindström, PhD, assistant professor of stem cell biology and regenerative medicine at the Keck School of Medicine of USC. Lindström is co-corresponding author of the team’s published report in Science, titled “Patterning human kidney organoids with synthetic Wnt-secreting organizers.” In their paper, the researchers reported, “Our findings link a spatial organizing geometry in the developing human kidney to controllable engineering in vitro.”
“Stem cell–derived organoids have emerged as systems for modeling organ development and generating complex tissue structures in vitro,” the authors wrote. Over the past decade, organoid work has relied on cells’ ability to self-organize into tissue-like structures, often in response to adding chemicals and proteins that act broadly in the whole organoid. “Although this capacity enables organoids to recapitulate many developmental programs, it limits experimental control over tissue architecture, often producing structures that vary between cultures and are difficult to engineer reproducibly,” the team continued. “Understanding how to impose spatial patterning in organoid systems is therefore an important challenge.”
In embryos, spatial patterning is often organized by localized signalling centers, known as developmental organizers. But how organizing geometry is controlled in the developing kidney, and whether it can be recreated in vitro, hasn’t been known.
For their reported study, the team combined spatial transcriptomics of the developing human kidney with synthetic engineering. “We mapped this organizing geometry in developing human kidneys and tested whether a minimal cue of localized WNT signaling could restore spatial control of nephron patterning in organoids,” they explained.
The project began by making tools to copy developmental signals. Postdoctoral researcher Fokion Glykofrydis, PhD, in the Morsut lab, engineered a “synthetic organizer” cell that secreted a Wnt protein that their spatial transcriptomics and other analyses indicated was involved in spatial patterning during kidney development. Graduate student Connor Fausto from the Lindström lab proposed an experiment to test how this Wnt-secreting cell would affect organoid nephrons.
The experiments revealed that the synthetic organizer enabled two key processes essential for building organs: controlling the identity of cells and influencing the shape of developing structures. The synthetic organizer serves as a localized and targeted source that secretes controllable amounts of specific Wnt proteins within the organoid itself. These are key signals that help shape the developing kidney. This creates a signaling environment much more similar to a naturally developing kidney and gives researchers a way to control where and how kidney structures form.
Co-corresponding author Leonardo Morsut, PhD, associate professor of stem cell biology and regenerative medicine, and biomedical engineering at the Keck School of Medicine and USC Viterbi School of Engineering, said, “With our approach, we are trying to control self-organization, and work with it as opposed to try to completely override it.”
Lindström expected Wnt to trigger nephrons to change their identity into cells capable of forming connections with the urine drainage system. What surprised him was that the nephrons also changed shape and elongated toward the source of the Wnt signal, which doesn’t happen when signals are delivered uniformly to the whole organoid. Compared with the developmental process seen in traditional kidney organoids, this elongation toward the Wnt source is more similar to what happens in a naturally developing kidney.
“A single, localized signal did two things at once. It changed what the cells became and physically pulled the tubules toward the source,” Lindström said. “You would not see that with a uniform chemical bath of signals.” Engineered WNT-secreting cellular organizers introduced into kidney organoids restored organizing geometry, the authors noted, “… biasing distal nephron differentiation and orienting nephron morphogenesis toward the signal source, which demonstrates that developmental signaling geometry can be reconstructed synthetically to control tissue patterning.”
The team identified a previously unrecognized axis, a direction along which the developing kidney organizes itself. Developmental biologists have long known about the nephron’s classic “proximal-distal (PD) axis,” which runs from its blood-filtering end to its urine-drainage end. The new axis is defined instead by how close each part of the nephron sits to the collecting duct, the tube system that drains urine and releases Wnt signals during development. Those signals tell the nephron what shape to take and which way to point.
“The study shows that there’s an undiscovered axis that sets up how a nephron looks and forms,” said Lindström. “It’s not every day that you find something new in human development at that level.”
Most kidney organoids contain only nephrons and lack the collecting duct that supplies this local Wnt signal, so they have no such axis and organize in a radially symmetrical pattern. By mapping how kidney cells respond to Wnt at specific locations in the developing kidney, the team recreated that environment in organoids with the synthetic organizer, producing structures that are both more developmentally faithful and more reproducible.
“Introducing tunable WNT-secreting synthetic organizers (SOs) in organoids restored canonical WNT responses, biased distal nephron differentiation, and oriented nephron morphogenesis toward the WNT source,” the investigators stated in summary. The combined results, they suggested, “… demonstrate that the spatial geometry observed in vivo can be reconstructed synthetically to control early nephron patterning and morphogenesis … Synthetic organizers provide a modular way to restore missing spatial interactions without reconstructing the entire collecting duct lineage, complementing approaches that rebuild collecting duct–to–nephron cellular interactions.”
For Morsut, the synthetic organizer is one of several tools his lab is building to control how tissues form, and the one he is most excited about, because it steers development in a way that is powerful but not intrusive. “The synthetic organizer is just a little cluster of cells that don’t build anything themselves,” said Morsut. “But they produce a powerful field that aligns the stem cells and gives them a direction.”
Synthetic organizers offer a modular strategy to reintroduce spatial signaling interactions that are often absent in conventional organoid cultures, the team suggested. “This approach should be broadly applicable to other organoid systems in which spatial signaling environments play instructive roles during development, providing a framework for linking developmental biology with the rational engineering of tissue architecture.
Aligning cells is something embryos do repeatedly as they build themselves, Morsut noted, and the study shows it can now be put to work in an engineering setting, steering the process toward a desired outcome. “At the beginning of my talks, I always show a video of embryonic development,” said Morsut. “You start from a single cell, and you get to a complete organism, and that’s as close to magic as it gets. Now, we open a possibility of controlling this magic technology for building organs. This study shows that we can do that, and I’m excited to see what others will do in other contexts.”
The post Synthetic Organizers Aid Creation of Reproducible Kidney Organoids from Stem Cells appeared first on GEN – Genetic Engineering and Biotechnology News.
Merck and Insilico Make Deals, Claude Science’s Debut, Vaccines for Neglected Diseases
More big biotech deals on the docket this week. First, Merck KGaA is buying Bio-Techne for $11.3 billion to expand its presence in high-growth life science markets. We dive into the details of this deal and then turn our attention to a $2.5 million collaboration to use artificial intelligence to find drug candidates for neuroimmune disorders. That deal involves Insilico Medicine and SK Biopharmaceuticals. Still on the theme of AI, we discuss Anthropic’s Claude Science, the latest entrant to the growing ecosystem of tech platforms specialized for biology, and a set of models for antibiotic design and vaccine target prediction. Lastly, we dig into two recent publications that discuss vaccines for Nipah virus and one of its relatives, and for treating schistosomiasis.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
Merck KGaA to Acquire Bio-Techne for $11.3B, Expanding Life Science Tools Presence
By Alex Philippidis, GEN Edge, June 25, 2026
Insilico, SK Launch Up-to-$2.5B Neuroimmune AI Drug Collaboration
By Alex Philippidis, GEN Edge, June 28, 2026
Claude Science Is Here, Antibiotics Designed by Text Prompt Among Applications
By Fay Lin, PhD, GEN Edge, June 30, 2026
Schistosomiasis Vaccine Shows Strong Immune Memory in Early Clinical Trials
GEN, June 29, 2026
Nipah and Hendra Viruses: Antibody Cocktail Provides Complete Protection in Hamster Model
GEN, June 26, 2026
Hosted by Corinna Singleman, PhD
Hosted by Jonathan D. Grinstein, PhD
The post Merck and Insilico Make Deals, Claude Science’s Debut, Vaccines for Neglected Diseases appeared first on GEN – Genetic Engineering and Biotechnology News.
Personalized Therapy Could Overcome Resistance in Metastatic Melanoma
Researchers at the University of Texas MD Anderson Cancer Center have identified a strategy to reverse resistance to standard treatment in BRAF-mutant advanced melanoma. Their findings, published today in Nature Communications, support using a biomarker-guided approach to improve outcomes for patients with treatment-resistant melanoma.
“Patients whose melanoma has stopped responding to standard therapies currently have very few effective treatment options,” said Vashisht Gopal Yennu Nanda, PhD, associate professor of melanoma medical oncology and translational molecular pathology at UT MD Anderson. “Our findings could help address this critical need for these patients by guiding clinicians toward combinations tailored to each individual’s tumors.”
About 50% of melanoma tumors carry BRAF mutations that drive uncontrolled tumor growth. Although the standard of care, consisting of a combination of BRAF and MEK inhibitors, is initially effective in most patients, about 80% will develop resistance within two years. In many cancers, but especially in melanoma, acquired resistance is often driven by the tumor increasing production of proteins from the BCL2 family, which block apoptosis and support the survival of cancer cells.
Yennu Nanda and colleagues tested the effects of adding a BCL2 inhibitor drug to the standard two-drug regimen in patient-derived xenograft models, which were established using melanoma tumors that had acquired resistance to standard therapy. Results showed that tumors that expressed high levels of BCL2 responded well to the triple combination, reversing resistance and inducing a complete tumor regression.
However, tumors that expressed high levels of MCL1—another protein from the BCL2 family—did not respond to this combination. In these tumors, the researchers tested an alternative treatment course adding an experimental MCL1 inhibitor to standard treatment, which successfully led to complete tumor regression.
“Targeted therapy works by shutting down the main signal driving melanoma growth, but tumors often have backup systems that keep them alive,” said Yennu Nanda. “By identifying which protein a tumor relies on for survival, we may be able to match patients to drug combinations tailored to their specific tumor biology.”
MCL1 inhibitors have previously shown promising antitumor activity, but early clinical trials flagged concerning heart-related side effects that have prevented them from moving through clinical development and receiving approval. In this study, however, the combination of an MCL1 inhibitor with standard BRAF-MEK inhibitors seemed to protect cardiac cells from the harmful effects associated with these experimental drugs.
“We did not anticipate that pairing these drugs would reduce MCL1 inhibitor toxicity,” said Michael A. Davies, MD, PhD, chair of melanoma medical oncology at UT MD Anderson. “If this finding is confirmed in clinical trials, it could give a second life to a class of drugs that has struggled to advance through development. It also reinforces that the most effective combinations are those that eliminate cancer while sparing healthy tissue.”
Building on these findings, the researchers are now working on analyzing tumor samples from a recent Phase II clinical trial in melanoma patients who received standard treatment and a BCL2 inhibitor, with the goal of studying whether MCL1 expression can predict clinical response. Down the line, their goal is to design clinical trials where melanoma patients are matched with drug combinations based on the expression of BCL2 or MCL1 biomarkers.
The post Personalized Therapy Could Overcome Resistance in Metastatic Melanoma appeared first on Inside Precision Medicine.

